Previous 10 | Next 10 |
June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. These small-cap biotechnology stocks when held in the long term can...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
Cancer therapeutics have come a long way in the last 10 years, with the rise of cancer immunotherapy and gene therapy providing ever-improving outcomes for patients. Investors keen on profiting from these ongoing and future advances in biomedical science will need to round out their portfolio wi...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 160 weeks of public selections as part of this ongoing live forward-testing resea...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with this Read more ...
Mersana Therapeutics (NASDAQ: MRSN ) has priced its public offering of 8M common shares at $19.00, yielding gross proceeds of $152M. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced ...
May 28, 2020 Palm Beach, FL – May 28, 2020 – Glioblastoma is a type of brain cancer. It’s the most common type of malignant brain tumor among adults. And it is usually very aggressive, which means it can grow fast and spread quickly. Glioblastoma multiforme is...
Mersana Therapeutics (NASDAQ: MRSN ) launches a public offering of 5M shares of common stock. More news on: Mersana Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...